Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC

Kwan, Wai SanJanneh, OmarHartkoorn, RubenChandler, BeckyKhoo, SayeBack, DavidOwen, Andrew2010-11-302010-11-302010-11-30200910.1111/j.1365-2125.2009.03462.xhttps://infoscience.epfl.ch/handle/20.500.14299/59902WOS:000269575200008center dot Antiretroviral protease inhibitors such as lopinavir and saquinavir have been shown to be substrates of ABCB1. Co-administration with the potent ABCB1 and CYP3A4 inhibitor, ritonavir, has shown improved pharmacokinetics and subsequent therapeutic effects of protease inhibitors. Darunavir is a recently licensed protease inhibitor with potent antiretroviral effects but has yet to be characterized as a potential substrate for drug transporters.darunavirefflux transportPBMCsHiv Protease InhibitorsIn-VitroAccumulationCellsIdentificationMrp1PolymorphismsModulationSaquinavirFamilyIntracellular 'boosting' of darunavir using known transport inhibitors in primary PBMCtext::journal::journal article::research article